• Home
• Company Info
  • Management Team
  • Bor-Wen Wu, PhD MBA
  • John Bomalaski, MD
  • Archie Prestayko, PhD
  • W. Jenny Kung, PhD
  • Wei He, PhD
  • Jim Thomson, PhD
  • Steve Wu
  • Advisory Board
  • Lloyd J. Old, MD
  • Steven A. Curley, MD
  • George Demetri, MD
  • Robert C. Jackson, PhD
  • Hsing-Jien Kung, MD PhD
  • Jedd D. Wolchok, MD PhD
  • Subsidiaries
  • Polaris Pharmaceuticals
  • TDW Pharmaceuticals
  • DRX Pharmaceuticals
  • DRX (Shanghai)
• Pipeline
  • ADI-PEG 20 (Oncology)
  • About Metastatic Melanoma
  • About Hepatocellular Carcinoma
  • Uricase-PEG 20
  • About Hyperuricemia
  • About Gout
  • About Tumor Lysis Syndrome
  • TNF-PEG 20
  • CK2 Inhibitor
  • ADI-PEG 20 (Antiviral)
  • About Hepatitis C Virus
  • Histidase-PEG 20
• Collaborations
  • Ludwig Institute for Cancer Research
  • Cleveland Clinic
  • South Florida VA Foundation
  • University of California - Davis
  • National Taiwan University
  • Barts and the London School of Medicine and Dentistry
• Literature
  • Polaris & Collaborators
  • ADI-PEG 20 (oncology)
  • Uricase-PEG 20:
  • TNF-PEG 20:
  • CK2 inhibitor:
  • ADI-PEG 20 (antiviral):
  • Related Publications
  • ADI general:
  • ADI (oncology) renal cell carcinoma:
  • ADI (oncology) combination therapy:
  • TNF cancer treatment:
  • CK2 inhibitor:
  • Histidase cancer treatment:
• Company News
• Contact

• Literature
• Polaris & Collaborators
• ADI-PEG 20 (oncology)
• Uricase-PEG 20:
• TNF-PEG 20:
• CK2 inhibitor:
• ADI-PEG 20 (antiviral):
• Related Publications
• ADI general:
• ADI (oncology) renal cell carcinoma:
• ADI (oncology) combination therapy:
• TNF cancer treatment:
• CK2 inhibitor:
• Histidase cancer treatment:

© Copyright The Polaris Group. All rights reserved.